National Perinatology Institute, Mexico City, Mexico.
Pediatrics. 2014 Apr;133(4):e904-9. doi: 10.1542/peds.2013-0652. Epub 2014 Mar 17.
To evaluate whether daily administration of Lactobacillus reuteri DSM 17938 reduces the frequency and duration of diarrheal episodes and other health outcomes in day school children in Mexico.
Healthy children (born at term, aged 6-36 months) attending day care centers were enrolled in this randomized, double-blind, placebo-controlled trial. They received L reuteri DSM 17938 (dose 10(8) colony-forming unit; n = 168) or identical placebo (n = 168) by mouth, daily for 3 months, after which they were followed-up after a further 3 months without supplementation.
Data from all children were included in the final analysis. L reuteri DSM 17938 significantly reduced the frequency and duration of episodes of diarrhea and respiratory tract infection at both 3 and 6 months (P < .05). Additionally, the number of doctor visits, antibiotic use, absenteeism from day school and parental absenteeism from work were significantly reduced in the L reuteri group (P < .05). A cost-benefit analysis revealed significant reductions in costs in the L reuteri-treated children. No adverse events related to the study product were reported.
In healthy children attending day care centers, daily administration of L reuteri DSM 17938 had a significant effect in reducing episodes and duration of diarrhea and respiratory tract infection, with consequent cost savings for the community.
评估每日给予罗特氏乳杆菌 DSM 17938 是否能减少墨西哥日托儿童腹泻发作的频率和持续时间以及其他健康结果。
本随机、双盲、安慰剂对照试验纳入了健康的日托儿童（足月出生，年龄 6-36 个月）。他们接受罗特氏乳杆菌 DSM 17938（剂量 10(8)菌落形成单位；n = 168）或相同的安慰剂（n = 168）口服，每日 1 次，持续 3 个月，之后在不补充的情况下再随访 3 个月。
所有儿童的数据均纳入最终分析。罗特氏乳杆菌 DSM 17938 显著减少了 3 个月和 6 个月时腹泻和呼吸道感染发作的频率和持续时间（P <.05）。此外，罗特氏乳杆菌组的就诊次数、抗生素使用、日托缺勤和父母旷工的次数也显著减少（P <.05）。成本效益分析显示，罗特氏乳杆菌治疗组的成本显著降低。未报告与研究产品相关的不良事件。
在日托中心的健康儿童中，每日给予罗特氏乳杆菌 DSM 17938 可显著减少腹泻和呼吸道感染的发作和持续时间，并为社区带来成本节约。
